Amydis lands $1.1M NIH grant for retinal test to spot ALS early
What's the deal? Amydis, a diagnostics biotech firm, has secured a $1.1 million Small Business Innovation Research grant from the National Institutes of HealthDealroom has a profile for this one. Try Dealroom →. The award, from the National Institute of Neurological Disorders and StrokeDealroom has a profile for this one. Try Dealroom →, funds a non-invasive retinal imaging test.
What's the endgame? The technology detects TDP-43 protein aggregates, biomarkers for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Amydis uses fluorescent tracers that bind to these aggregates, letting clinicians read them with standard ophthalmic equipment — using the eye as a window into brain pathology.
Why the retina? Researchers increasingly treat the retina as a direct extension of the central nervous system. Because the eye shares embryonic origins with the brain, it can serve as a non-invasive surrogate for tracking neurodegeneration.
Why now? Current diagnostic paths for ALS and FTD are often invasive, requiring cerebrospinal fluid analysis or post-mortem tissue examination, according to the National Institute of Neurological Disorders and Stroke. Amydis aims to detect protein buildup before advanced symptoms appear — a stage when disease-modifying therapies work best but that traditional methods struggle to capture.
What could go wrong? The current phase focuses on refining imaging protocols and validating tracer sensitivity. Amydis must still prove its retinal findings correlate with disease progression in human subjects.
The signal: At $1.1 million, the grant sits in the 28th percentile for deal size, a modest but targeted bet. If validation holds, it points toward cheaper, less invasive screening for TDP-43 proteinopathies entering routine neurological and ophthalmological care.
Read more: memesita.com
Image credit: Ivan Radic
